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COMMENTARY
The birth of an infant and its rapid discharge from the hospital create a special set of circumstances in which clinical actions begun in the nursery must be communicated to an identified external provider for follow-up. The risk of a break in the flow of information and a failure of follow-up is ever present, particularly in high volume obstetric services and in communities where access to primary care is suboptimum. In these situations it is especially important that parents be well informed about screening or other programs that involve their infants and the implications for continuing care.
Although the authors point out that little is known about the effect of educational materials on compliance, such ignorance should not preclude a willingness to gamble on the usefulness of redundancy in the dissemination of information. And similarly, even though there is a lack of studies that assess what information parents should have about newborn screening and how best to provide it, there should be no disagreement that, however it is presented, health information should be complete and easy to understand, qualities that are not consistently found in the materials reviewed here.
The challenges of successfully screening over 4 million infants annually in some 50 different state programs are enormous. Given the variations in the kinds of conditions being screened, in the follow-up arrangements, and in consent requirements, the creation of clear and simple educational materials would not be an easy task. Nevertheless, it should be attempted, preferably at the national level. Perhaps, in time, such an approach could open the way to the development of greater uniformity and consistency in all aspects of the programs. 
SUMMARY
In what was probably the first population based study of the rate of follow-up testing of children with elevated screening levels of blood lead, the authors identified 3682 Medicaid-enrolled children 6 years of age or younger with levels of 10 mg/dl or higher between January 1, 2002, and June 30, 2003, in Michigan, where laboratories are mandated to report results of lead testing. Medicaid demographic and encounter data were linked to testing results and analyzed for the likelihood of a follow-up test within 180 days of the initial report. The children were predominantly Hispanic or nonwhite (86.3%), urban (97.3%) and living in high lead risk ZIP code areas (95.7%).
Overall, 53.9% of children received a follow-up test. Those with the highest screening levels (Q45 mg/dl) had the highest follow-up rates (94%) compared to those in the 10-19 mg/dl range (51%), and younger children were more likely to be followed up than older ones. Calculation of relative risk (RR) showed that, contrary to a stated hypothesis, the children who were Hispanic or nonwhite, urban, and living in high lead risk ZIP codes were less likely to have follow-up testing, (RR 0.91, 0.92, and 0.94, respectively) . Specifically, white children received a follow-up test in 66% of cases compared to 52% for those who were Hispanic and non-white. When children did receive follow-up, 47.5% still had elevated levels. Of children who did not have follow-up testing, over half (58.6%) had had at least one medical encounter billed to Medicaid in the 180 days following the initial screening test. All these encounters were considered to be Bmissed opportunities^; 13.2% of them were actually coded as preventive care.
COMMENTARY
The good news is that elevated lead levels in young children in the United States have declined dramatically in recent years. According to data reported from the National Health and Nutrition Examination Surveys (NHANES) that compared the 1991-1994 and 1999-2002 Surveys, for children aged 1-5 years the percentage who had elevated levels (Q10 mg/dl) declined from 4.4 to 1.6 and for Black, nonHispanic children the percentages dropped from 11.2 to 3.1.* The bad news is the widespread failure to do follow-up testing of children who screen positive, compounded by racial-ethnic disparities, as summarized above. If the Michigan data is applicable to the whole country, which could likely be the case, then over half of the estimated 310,000 children at immediate risk of poisoning nationwide* are not receiving proper care.
Policies on lead abatement have clearly had an important impact on the prevalence of lead poisoning in children, but the current approach to follow-up of lead-exposed children, which relies on the primary care provider, is allowing far too many at-risk children to miss the next step of recommended care. Perhaps the time has arrived for public health departments, which usually become involved after a case is confirmed, to add the responsibility of tracking children with positive screens to ensure they receive appropriate follow-up. The tracking process might in itself enhance providers_ awareness of recommended procedures and also reduce the frequency of missed opportunities.
The well-known effect of increased lead burden on cognitive development, coupled with the racial-ethnic disparities shown here, demands a response from the nation. For this as well as many other reasons, strengthening the public health infrastructure to enable it to meet its responsibilities should be made a priority. 
SUMMARY
Estimates of the prevalence of attention-deficit/hyperactivity disorder (ADHD) and its treatment have previously been based on local samples in which the disorder's prevalence has ranged from 2 to 18%. This report provides data derived from a national sample, the 2003 National Survey of Children's Health (NHSC). NHSC is a telephone survey of households with children in which parents or guardians are asked questions about a child's physical and emotional health. In this case, they were asked, for children aged 4-17 years, whether a health professional has ever said that a child has ADHD and if so, whether the child is currently taking medication for it. Nationally, 7.8% or about 4,418,000 children had ever had ADHD diagnosed, but there were large variations by state, ranging from 5.0% in Colorado to 11.1% in Alabama. An estimated 2,473,000 children, 4.3% of the population, were being given medication for the disorder, again with wide differences in states, from 2.1% in California to 6.5% in Arkansas. Overall, 56.3% of children who had ever had the diagnosis of ADHD were under treatment. The diagnosis was reported more often in boys than girls (11.0 to 4.4%) and older (Q9 years) rather than younger children (9.7 vs. 4.1%). Prevalence was higher in white children (8.6%) and lowest in Hispanics (3.7%) and non-English speaking families (1.3%). Children in poor households had a somewhat higher prevalence than the overall rate, but children without health insurance were much less likely to have been diagnosed (4.9%). The proportion of children taking medication was lower among children older than 13 *Schwemberger JG, Mosby JE, Doa MJ, et al. Blood Lead Levels-United States, 1992 -2002 . MMWR Morb Mortal Wkly Rep. 2005 54:513-516. LOBACH years. It was higher in white children, better educated, non-Hispanic, and Englishspeaking families; it was very low in uninsured children. No information was available about other treatment modalities for ADHD because the NHSC inquires only about medication.
COMMENTARY
Although well-established criteria for the diagnosis of ADHD exist and have been widely promulgated, concerns continue to be heard that the condition is often either under or over diagnosed and may be overmedicated. This report, with its documentation of wide ranging geographic and sociodemographic variations in prevalence will do little to dispel the uncertainties about diagnostic consistency, but it does suggest that overuse of medication is not a comparable problem. Even taking into account that the survey only identified medication being currently administered, still even the youngest age groups, who would be less likely to have a past rather than current history of medication, showed that fewer than two-thirds of those with a diagnosis were also said to be taking medication.
While certain variations in prevalence, such as the gender and age differences, and the lack of recognition and treatment in uninsured children are not unexpected, what are we to make of the low prevalence reported in more vulnerable populations such as Hispanics? Is this group being under diagnosed or are whites, and to some extent blacks, where the reported prevalence is only slightly lower than that of whites, being over diagnosed? Why do children from the poorest families have the highest rates, while children from the least educated families have rates below the median? The numbers reported here call out for further statistical analysis, which might shed some light on these puzzles. But information about the true prevalence of this disorder in different groups and places awaits a population study that, difficult as it might be, examines the actual occurrence of the disorder rather than its reported diagnosis.
